Zealand Pharma A/S (LON:0NZU)

Market Cap	5.59B
Revenue (ttm)	6.95M
Net Income (ttm)	-119.63M
Shares Out	n/a
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,795
Average Volume	10,538
Open	723.50
Previous Close	781.69
Day's Range	717.50 - 770.00
52-Week Range	38.03 - 107.62
Beta	n/a
RSI	44.96
Earnings Date	Feb 20, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 253
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZU

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK